Multiple sclerosis (MS) is an autoimmune disease in which the body's immune system attacks the myelin (a fatty protective material) that coats nerve fibers in the nervous system, causing paralysis and impairing motor abilities and vision.
Multiple sclerosis is not yet a cure, but there are drugs that slow the progression of the disease, one of which is known as Copaxone,natureAnd one of 15's top-selling drugs in the world, with sales of 4.8 billion in 2014.
A new study from the Hebrew University of Jerusalem shows thatCBD (Cannabidiol), as well as the extract of the rich cannabis strain in CBD 'AvidkelOf Tikkun Olam, there is greater efficacy than Copaxone in treating the symptoms of multiple sclerosis.
Since COPAXONE treatment costs are particularly high, allowing the use of CBD, which is much cheaper to produce, could lead to severe economic damage to the Israeli pharmaceutical company, which offers Copaxone at a cost of 91,401 per year. There is, of course, a difference in the dangerous side effects after taking Copaxone, compared to CBD, which has no dangerous side effects at all.
The study Was conducted by Prof. Ruth Galili, one of the world's oldest and most respected researchers in the field of medical cannabis research Further studies On the CBD. It was published in the Journal of Inflamopharmacology at the end of the week (5.10).
In the introduction to the study, CBD has known anti-inflammatory properties, and in animal experiments it has shown efficacy in treating a variety of autoimmune diseases such as Arthritis, diabetes mellitus Inflammatory bowel disease such as Crohn andColitis.
The study examined the efficacy of pure CBD, Avidacillus cannabis oil, and Teva's Copaxone drug in reducing the symptoms of multiple sclerosis in mice.
The mice received injections of substances that caused their immune system to attack the myelin coating of nerve fibers in the nervous system - as was done in experiments to simulate multiple sclerosis.
The autoimmune encephalomyelitis occurs in waves - that is, the symptoms appear for a few days, and then there is an improvement for a few days, and then a further worsening and recurrence. During the 60 study days were recorded 3 outbreaks of the disease, with relaxation in the symptoms between outbreak and outbreak.
When the mice began to show symptoms of paralysis, usually after 9-11 days, they were divided into 4 groups with 8 mice in each group:
- The first group received injections of pure CBD at the dose of 5 mg / kg.
- The second group received injections of ibdecal extract at a dose of 50 mg / kg.
- The third group was treated with subcutaneous injections of Copaxone at a dose of 50 mg / kg.
- The fourth group received placebo - injections of saline.
The researchers examined the mice closely for 60 day of treatment and rated their symptoms from 1 to 5 on an acceptable scale of paralysis levels taken from previous studies.
Both CBD and Avidecal were particularly effective in improving clinical symptoms during all three outbreaks of the disease.
At the peak of the first outbreak of the disease, during 14-18 days of the experiment, pure CBD treatment reduced the symptoms In 56% And the treatment of abidecal extract reduced the symptoms In 54.3% On average, compared to the control group.
At the height of the second outbreak of the disease, during 31-35 days of the experiment, CBD treatment reduced the symptoms in 39.1%, and the treatment with Avidecal extract reduced them by an average 48.9%.
At the height of the third outbreak of the disease, during 41-49 days of the experiment, CBD treatment reduced the symptoms in 50.4% and the treatment of the epididym reduced them by an average 49.7%.
In a comparison of the groups treated with CBD and ibidekel for the coxone-treated mice, CBD and ibdecl were found to be more efficient Copaxone for the first two outbreaks of the disease, and equally effective for the third outbreak.
In the 11-13 trial period, during the first outbreak of the disease, CBD reduced the symptoms in 33.5%, AVIDCEL in 40.3%, and COPAXONE only in 21.1% on average compared to the control group.
In the 24-26 trial period, during the second outbreak of the disease, CBD reduced the symptoms in 47.2%, Avidkal in 39.7%, and Copaxone only in 20.8%.
During the third outbreak, the three treatments showed very high efficacy - CBD with a reduction of 65% in the symptoms, Avidkil with a reduction of 80 in the symptoms, and Copaxone with a reduction of 76.8%.